LT-β-R-Ig Purification via Hydrophobic Interaction Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Biologic manufacturing faces challenges in identifying and separating product-related impurities, such as inactive forms and aggregates of LT-β-R-Ig fusion proteins, which are difficult to detect and remove due to their similar characteristics to the active form, posing safety and efficacy concerns.
Innovation Solution
A method involving hydrophobic interaction chromatography (HIC) and mixed mode chromatography is employed to separate biologically active LT-β-R-Ig fusion proteins from inactive forms and aggregates, utilizing salt gradients and specific resin interactions to achieve high purity and minimize protein loss.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional purification methods are used, then the active form of LT-β-R-Ig can be obtained, but inactive forms and aggregates cannot be effectively separated due to similar characteristics
Solution Approach 1:
The patent employs hydrophobic interaction chromatography (HIC) which changes the physical-chemical parameters of the purification process by utilizing hydrophobic interactions. The method uses salt gradients to modulate the hydrophobicity of protein surfaces, enabling separation of inactive forms and aggregates from active LT-β-R-Ig based on subtle differences in their hydrophobic characteristics that are not detectable by conventional methods.
Solution Approach 2:
The patent introduces salt as an intermediary substance in the HIC process. The salt gradient acts as a mediator that progressively exposes or masks hydrophobic regions on protein surfaces, allowing inactive forms and aggregates to be separated from the active form through differential binding and elution behaviors on the hydrophobic chromatography resin.
2Manufacturing precision
If temperature is reduced during cell culture to decrease inactive molecules, then inactive forms are reduced, but production yield decreases
Solution Approach 1:
The patent applies preliminary action by performing hydrophobic interaction chromatography on the crude cell culture supernatant before further purification steps. The HIC process pre-separates inactive forms and aggregates from active LT-β-R-Ig, allowing subsequent purification steps to focus on removing other impurities while maintaining high yield. This preliminary separation avoids the need for prolonged low-temperature culture that would reduce productivity.
Solution Approach 2:
The patent replaces the mechanical/physical approach of low-temperature culture with a chemical/chromatographic approach (HIC). Instead of relying on temperature control to prevent inactive form formation, the method uses hydrophobic interaction chromatography to selectively separate inactive forms after production, thereby maintaining normal production temperatures and productivity while achieving high purity.
3Productivity
If scaling up production to increase yield, then more active protein is produced, but aggregation increases significantly
Solution Approach 1:
The patent extracts aggregates and inactive forms from the crude protein mixture using hydrophobic interaction chromatography. The HIC resin selectively binds hydrophobic regions exposed on aggregate surfaces and inactive forms, allowing these impurities to be removed in the flow-through or early elution fractions, while active monomeric LT-β-R-Ig elutes later with high purity regardless of production scale.
Solution Approach 2:
The patent utilizes parameter changes in the HIC process, specifically varying salt concentration gradients, to control the elution of different protein species. By optimizing the salt gradient profile, the method achieves separation of aggregates and inactive forms from active protein, maintaining high purity even when scaling up production to increase yield.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively reduces inactive forms and aggregates to less than 1% and 2%, respectively, ensuring the production of high-purity, biologically active LT-β-R-Ig fusion proteins suitable for pharmaceutical use, enhancing both manufacturability and patient safety.
Implementation Method 1
loading a mixture comprising biologically active LT-β-R-Ig fusion proteins and biologically inactive LT-β-R-Ig fusion proteins onto a butyl hydrophobic interaction chromatography (HIC) resin and contacting the resin with a solution comprising a salt gradient
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention provides methods and compositions for separating impurities during the manufacture of immunoglobulin (Ig) fusion proteins. Examples of impurities which may be removed in accordance with the methods of the invention include inactive forms of the Ig fusion protein and/or aggregates.